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Synopsis  
Illness perceptions have strong links to outcomes in chronic disease. This study shows that 
some illness perceptions in newly-diagnosed patients with glaucoma or ocular hypertension 
differ to illness perceptions in patients who have been diagnosed for at least two years, 
overall illness perceptions were equally negative in all groups. 
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ABSTRACT 
Background/aims: To determine whether self-reported illness perceptions in newly-diagnosed 
patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) are more 
negative compared to peers who have lived with their diagnosis for more than two years. 
Methods: A cross-sectional study of 58 newly-diagnosed patients with POAG and OHT recruited at 
their first clinic visit. Electronic patient records were used to identify similar patients (n=58, related 
by age and severity of visual field loss) who had their diagnosis for > 2 years. All participants 
completed the Brief Illness Perception Questionnaire (BIPQ), EQ5D general health measure and Type 
D Personality Scale (DS14). 
Results: Average BIPQ scores were similar for people newly-diagnosed with POAG and POAG 
diagnosed > 2 years, and were no different to newly-diagnosed OHT and OHT diagnosed > 2 years 
POAG (p=0.46). An analysis correcting for personality type (DS14) and general health (EQ5D) 
indicated newly-diagnosed patients with POAG to have marginally better illness perceptions on 
individual BIPQ items quantifying impact on life in general, experience of symptoms and 
‘understanding’ of their condition (all p<0.01). In contrast POAG patients with a diagnosis >2 years 
understood better their condition to be long-term (p<0.01).  
Conclusions: Some illness perceptions differed between newly-diagnosed people and patients living 
with their diagnosis for >2 years. Illness perception for people with manifest glaucoma and at risk of 
glaucoma (OHT) were similar; the latter might benefit from an intervention at diagnosis that highlights 
the better prognosis for OHT compared to POAG. 
Keywords; 
glaucoma; ocular hypertension; chronic illness; illness perceptions; illness representations; lay beliefs 
of health and illness; self-regulation; illness cognitions. 
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INTRODUCTION 
Illness perceptions are feelings or beliefs that influence a person’s psychological response to their 
illness. These perceptions are, for example, associated with clinical outcomes, coping behaviours and 
adherence to treatment [1, 2]. A substantial body of research on illness perceptions in chronic 
disease exists but studies in people with primary open angle glaucoma (POAG) and ocular 
hypertension (OHT) are uncommon [3, 4, 5].  
Interesting observations about negative illness perceptions at the point of diagnosis have been 
revealed in patients with POAG [6, 7]. Some of this negativity is likely attributed to the fear of going 
blind [8, 9]. Indeed, it has been shown that simply giving a diagnosis of POAG negatively affects 
measures of quality of life [8, 10]. Interviews with patients with POAG reveal initial feelings of fear 
were replaced by a more reasoned perspective over time [11]; this seems reasonable given most 
treated patients will not suffer significant visual impairment in their lifetime [12, 13].  Perhaps a 
newly-diagnosed patient may consider their condition will have a significant impact on them only to 
revise their view once they have the condition for a period of time; this has not been assessed in 
people with POAG/OHT. A better understanding of this idea has clinically relevant implications about 
how ‘diagnosis’ of POAG/OHT should be handled and communicated. 
One way to examine illness perceptions in POAG would be to ask patients directly and subject the 
responses to qualitative analysis [7, 11]. Alternatively, patient reported outcome measures (PROMs) 
have been used to quantify illness perceptions in chronic conditions [14, 15].  Results from PROMs 
measuring illness perceptions have been linked to self-management behaviours, including 
attendence to follow-up appointments [16] and have also been shown to be related to decline in 
social and physical functioning [17, 18] in a variety of conditions. A widely used and validated PROM 
instrument is the Brief Illness Perception Questionnaire (BIPQ)) [19, 20, 14]. We therefore use the 
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BIPQ in conjunction with other PROMs of well-being and personality allied to a measure of patients’ 
visual function to assess patients’ illness perceptions.  
We aim to quantify illness perceptions in patients with POAG and OHT. Our primary hypothesis 
centres on newly-diagnosed POAG and OHT patients having worse illness perceptions when 
compared to a group of patients who have lived with a diagnosis for more than two years. 
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MATERIALS and METHODS 
We used a cross-sectional study involving patients recruited from two clinical centres in England 
(Moorfields Eye Hospital NHS Foundation Trust (Bedford Hospital) and North West Anglia NHS 
Foundation Trust (Hinchingbrooke Hospital)). Newly-diagnosed patients were introduced to the study 
at the end of the clinic visit at which they were first diagnosed. For the purpose of simplicity, in the 
methods and results we refer to these participants as cases. In addition, patients who had held a 
diagnosis of more than two years (but less than five years) were identified from an electronic patient 
record (EPR; Medisoft, Leeds, UK) used at the participating clinics. We refer to these participants as 
controls.  
 
The study was approved by the North West - Liverpool East NHS Research and Ethics committee and 
it adhered to the tenets of the Declaration of Helsinki. All participants gave their informed written 
consent prior to taking part. Data was anonymised and stored securely. 
 
Study participants (> 40 years) had a diagnosis of POAG or OHT established by standard ophthalmic 
examination in the participating clinics. Participants were only included if they had no other ocular 
disease (except for previous uncomplicated cataract extraction) and a visual acuity of better than 0.3 
logMAR in each eye with astigmatism of less than 2 dioptres. All POAG participants had visual field 
(VF) loss in at least one eye as measured by a Humphrey Field Analyser (Carl Zeiss Meditec, Dublin, 
CA) using the Swedish Interactive Threshold Algorithm (Standard 24-2). Goldmann Applanation 
Tonometry was used to measure intraocular pressure.  
Cases were identified by convenience sampling with an effort to select controls by ‘matching’ at a 
group level to age and VF severity (for POAG) to provide a representative cross section of patients. In 
other words, to allow for an age-related and disease severity-related analysis. In the POAG groups, 
mean deviation (MD) in the least affected eye (the eye with the better MD) was used as a measure 
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for disease severity [12]. This was taken from the VF recorded in the EPR at the time of diagnosis 
(cases) or at the time closest to the date when a questionnaire pack was returned.  
A questionnaire pack, including a participant information sheet and consent form, was given to 
participants at the end of their clinic visit and returned by post; controls received and returned packs 
by post. Questionnaire packs included three validated instruments designed to measure illness 
perceptions, general health and personality type, respectively. 
[1] Brief Illness Perception Questionnaire (BIPQ) - The BIPQ has been widely used to investigate 
illness perceptions in chronic illness [14, 15, 19]. Eight items are scored on a 0-to-10 scale with 80 
representing the most negative illness perceptions. An open-ended styled ninth item asks patients to 
list the three most important causal factors for their illness. The original version of the BIPQ uses the 
word ‘illness’ but this was replaced by ‘glaucoma’ or ‘ocular hypertension’ for this study.  
[2] EQ5D– The EQ5D-3L [21] is a commonly used general health PROM and is approved in the United 
Kingdom (UK) by the National Institute for Health and Care Excellence as a general health measure for 
health economic analysis. Five items are scored either 1 (no problems), 2 (some problems) or 3 (severe 
problems) on the domains of mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Codes were translated into an index score ranging from 1 (perfect health state) 
to -0.624 (worst health state) using an existing scoring system [22].  
 
[3] Type D Scale personality questionnaire (DS14) – The DS14 is widely used to measure negative 
affect (e.g. general worry, gloom) and social inhibition (e.g. reticence, lack of self-assurance) [23] . 
This instrument has seven items for negative affect and social inhibition, respectively. Each item is 
scored from 0 (least distressed) to 4 (most distressed).  
 
We hypothesised cases would have worse average BIPQ when compared to controls. Sample size 
calculations (with power and statistical significance set at 80 and 5% respectively) were based on 
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detecting a small 5-point (out of 80) difference in overall mean BIPQ score between cases and 
controls. Using an estimate of standard deviation (SD) of mean scores of 7.5 points from a previous 
study [19] gave a suggested minimum sample size of 28 participants per group, which was our 
recruitment target.   
 
Data analysis 
We compared mean BIPQ score, age, best eye MD (BEMD), worse eye MD (WEMD), EQ5D index 
score and DS14 between cases and controls for the POAG and OHT groups. All individual data 
distributions were checked for normality. Univariate association between overall BIPQ against age, 
DS14 and EQ5D index score was explored to assess covariance in the data. 
Average score from each of the eight separate BIPQ items was also compared between cases and 
controls for the POAG and OHT groups using Multivariate Analysis of Covariance (MANCOVA); this 
corrects for any covariance from age, DS14 and EQ5D and is robust against multiple comparisons. A 
value of p<0.01 was considered statistically significant to further reduce the possibility of a false 
positive result. The scores from the separate BIPQ items are not assumed to follow a normal 
distribution. Instead, residuals from the MANCOVA were examined for signs of non-normality to 
make sure the approach was valid. 
Item 9 of the BIPQ asked participants, ‘to list, in rank order, the three most important factors that 
you think caused your glaucoma/ocular hypertension’. Two authors (LM and DPC) independently 
coded the first written response into categories following a prescription used in previous research 
[19]. Any disagreements were arbitrated with a joint consultation by all authors and groupings of 
coded responses were assessed with descriptive statistics.  All statistical analyses were done with 
SPSS Statistics 24 (IBM Corp., Somers, NY).  
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RESULTS 
The recruitment period for the study ran from January to November 2015. Questionnaires were 
completed by 124 participants with eight excluded because of incomplete consent or unreliable VFs. 
Our final sample of participants (52% male) consisted of 58 cases and 58 controls. Participants were 
nearly all Caucasian (98%) with 93% educated to at least a high school level and 32% self-reporting 
degree-level or professional qualification.  
POAG cases and controls were well related for age, BEMD, WEMD, and DS14 (Table 1).  POAG 
controls had slightly worse average self-reported general health (EQ5D) when compared to POAG 
cases (p=0.03). For our OHT study groups the cases and controls were similar for age, EQ5D and 
DS14. 
Table 1 – Mean (standard deviation) age, BEMD, WEMD, EQ5D index and DS14 for each of the four 
study groups.  
 n Age (y) BEMD 
(dB) 
WEMD 
(dB) 
EQ5D 
Index 
DS14  
POAG 
Case 
 
30 
 
73 
(9) 
 
-4.8 
(4.3) 
 
-9.0 
(4.8) 
 
0.77 
(0.22) 
 
40 
(11) 
 
Control 31 71 
(8) 
-5.1 
(5.1) 
-9.2 
(5.9) 
0.89 
(0.13) 
36 
(10) 
 
  p=0.33 p=0.83 p=0.96 p=0.03 p=0.20  
OHT        
Case 28 63 
(10) 
- - 0.92 
(0.11) 
38 
(10) 
 
Control 27 65 
(13) 
- - 0.86 
(0.17) 
36 
(8) 
 
  p=0.45 - - p=0.19 p=0.44  
 
For our primary outcome, mean (standard deviation; SD) BIPQ score for POAG cases and POAG 
controls was 31 [10] and 34 (13) respectively; these values were not significantly different 
(independent t-test; p=0.30). Similarly, mean (SD) BIPQ score for OHT cases (28 [11]) and OHT 
controls (28 [9]) were not significantly different (independent t-test; p=0.90). These results indicate 
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that, on average, illness perceptions are similar in people newly-diagnosed compared to those that 
have their diagnosis for at least two years. Moreover, averages for all four groups were not different 
(one–way ANOVA; p=0.46). Therefore, on average, overall illness perceptions in this sample of 
people with POAG and OHT are similar. 
There was no statistically significant association for BIPQ score against age (r=0.11; p=0.29). There 
was a weak but statistically significant univariate association for BIPQ against DS14 (r=0.26; p=0.01) 
and against EQ5D (r=0.28, p=0.04), suggesting illness perceptions are marginally worsened by a 
distressed personality and worse general health.  
Estimated marginal means with 95% confidence interval (CI) give a sense of the distribution of scores 
for all eight individual BIPQ items (Table 2). Statistically significant differences between groups on each 
item are reported from a comparison of adjusted means using a MANCOVA adjusted for DS14 and 
EQ5D scores. In this analysis, statistically significant effects occurred in four items in POAG patients. 
These average effects were all small in magnitude, mostly less than an average of 2 points on a 10-
point scale.  The largest effect was for the item about how long a participant thought POAG will last. 
In comparison to newly-diagnosed patients, people with POAG for >2 years better understood their 
condition will last for a ‘long time’. In comparison to newly-diagnosed patients, people with POAG for 
>2 years feel slightly more affected by the condition and experienced more symptoms. The latter is 
interesting given disease severity in the two groups was similar on average. Perhaps surprisingly, 
newly-diagnosed patients claim to understand their condition slightly better than those who have had 
POAG for >2 years. There were no statistically significant differences between cases and controls for 
people with OHT on any of the BIPQ items. 
Some of the average values for items (Table 2) are noteworthy. For example, most participants 
understood their POAG/ OHT is going to last for ever but a number did not. There was also a wide 
response to the question about control over POAG/ OHT revealing that many participants felt they 
did not have good control over their condition.  
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Table 2 – MANCOVA results for differences between POAG cases and controls, and OHT cases and 
controls for the eight items of the BIPQ. Mean scores (out of ten) shown are estimated (marginal) 
means and 95% confidence interval (CI), adjusted for DS14 and EQ5D index scores. The p values 
marked with * denote a significance level of <0.01 
 
One-hundred and six (91%) participants gave at least one written response to the open-ended item 
asking for the three most important causes (in rank order) for POAG/OHT. We only considered the 
 POAG Estimated 
marginal mean 
(95% CI) 
p OHT Estimated 
marginal 
mean (95% 
CI) 
p 
How much does your 
OAG/OHT affect your life? 
(1=little affect) 
Case 1.2  
(0.4, 2.0) 
<0.01* Case 1.2 
(0.7, 1.8) 
0.90 
Control 3.4  
(2.6, 4.1) 
Control 1.3 
(0.7, 1.9) 
How long do you think your 
OAG/OHT will continue?  
(10 = a long time) 
Case 7.0 
(5.9, 8.0) 
<0.01* Case 6.1 
(4.8, 7.4) 
0.28 
Control 9.4  
(8.4, 10.4) 
Control 7.2 
(5.8, 8.6) 
How much control do you 
think you have over your 
OAG/OHT? (1=little control) 
Case 4.5  
(3.1, 5.8) 
0.92 Case 5.6 
(4.2, 7.0) 
0.29 
Control 4.6 
(3.3, 5.9) 
Control 4.5 
(3.0, 6.0) 
How much do you think 
your treatment can help 
your OAG/OHT? (10=very 
helpful) 
Case 2.6 
(1.7, 3.6) 
0.25 Case 2.8 
(1.8, 3.7) 
0.38 
Control 3.4 
(2.5, 4.3) 
Control 3.4 
(2.4, 4.4) 
How much do you 
experience symptoms from 
your OAG/OHT?  
(1 = few symptoms) 
Case 1.0 
(0.3, 1.7) 
<0.01* Case 1.2 
(0.5, 1.9) 
0.86 
Control 2.7 
(2.0, 3.3) 
Control 1.3 
(0.5, 2.1) 
How concerned are you 
about your OAG/OHT? 
(10 = very concerned) 
Case 5.2 
(3.9, 6.5) 
0.33 Case 4.7 
(3.6, 5.8) 
0.33 
Control 6.1 
(4.9, 7.4) 
Control 3.9 
(2.7, 5.1) 
How well do you think you 
understand your OAG/OHT?  
(1= little understanding) 
Case 5.9 
(4.9, 6.9) 
<0.01* Case 4.4 
(3.3, 5.5) 
0.20 
Control 3.9 
(3.0, 4.9) 
Control 5.5 
(4.3, 6.7) 
How much does your 
OAG/OHT affect you 
emotionally? (10=very 
emotional) 
Case 1.6 
(0.7, 2.5) 
0.05 Case 2.0 
(1.3, 2.7) 
0.39 
Control  3.1 
(2.3, 3.9) 
Control  1.5 
(0.8, 2.3) 
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first written response in the list where participants (n=46) gave more than one cause. The summary 
of the coded responses, stratified by cases and controls, are shown in Table 3. Most cases (60%; 95% 
CI 45 to 74%) and controls (59%; 95% CI 45 to 72%) who completed item 9 correctly identified at 
least one known major risk factor [24]. It is noteworthy that 5% (95% CI 1% to 11%) of control 
participants, despite living with their diagnosis >2 years actively wrote, “don’t know” when asked for 
the cause of their condition. 
 
Table 3 – Frequency of responses by group to Q9 of the BIPQ [19], ‘Please list, in rank order, the 
three most important factors that you think caused your glaucoma/ocular hypertension’.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Case 
(n = 50) 
Control 
(n=56) 
Hereditary/Genetics – it runs in my family 19 
(38%) 
26  
(46%) 
Aging 8  
(16%) 
4  
(7%) 
Elevated intraocular pressure  3  
(6%) 
3 
(5%) 
Don’t know 1 
(2%) 
3  
(5%) 
Other conditions (including other eye disease)  5  
(10%) 
8  
(14%) 
Chance or bad luck  8 
(16%) 
3 
(5%) 
My own behaviour (including not seeing an optometrist 
regularly) 
4  
(8%) 
1 
(2%) 
My emotional state (e.g. anxiety, stress, worry)  0  
(0%) 
3  
(5%) 
Lifestyle (e.g. smoking, reading, living in Asia) 2  
(4%) 
5 
(9%) 
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DISCUSSION  
In a cross-sectional study we used an established method of measuring illness perceptions [19] to 
investigate average differences between newly-diagnosed POAG/OHT patients (cases) and those 
with a diagnosis of more than two years. Results indicate no difference in overall illness perceptions 
between the cases and those with a diagnosis of more than two years. Therefore, perhaps 
surprisingly, in this group of people, a new diagnosis of POAG/OHT does not precipitate a sudden 
feeling of negative illness perceptions when compared to other people who have lived with the 
condition for more than two years.  
Our findings represent new knowledge about illness perceptions in people with POAG/OHT. For 
example, results suggest diagnosis may not be as distressing as previous studies have indicated [6, 7, 
10]. Overall illness perceptions of our participants were, for example, similar to those from other 
studies that have used BIPQ to assess heart palpitations [14] or pre-treatment pulmonary 
tuberculosis [15]. In contrast, scores were lower on average than those found in people with 
diabetes [19]. These comparisons allow illness perceptions of POAG/OHT to be placed on a spectrum 
of chronic disease, but it may not be meaningful because of differences in the type of study and 
study populations.  
Secondary analysis of individual BIPQ items, when corrected for patient’s level of distressed 
personality (measured by DS14) and self-reported general health (measured by EQ5D) revealed 
interesting results. Unsurprisingly, newly-diagnosed POAG patients held less realistic beliefs about 
their condition compared to people who had the diagnosis >2 years. Moreover, newly-diagnosed 
POAG patients reported having less severe symptoms compared to those who had the diagnosis >2 
years, despite the two groups having similar average VF loss. In addition, POAG patients with a 
diagnosis for > 2 years had a more realistic perception of how long their illness would last compared 
to those newly-diagnosed. Remarkably, around one-third of the latter scored less than five on this 
item, indicating that they felt their condition would not last a long time.  Other studies, in other 
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conditions, suggest patients who do not understand their illness to be long term are more likely to 
abandon their treatment programmes when compared to those who comprehend their illness to be 
chronic [25, 26]. This suggests more should be done, at the point of diagnosis, to make sure patients 
are aware that their condition is permanent.   
POAG cases reported they understood their condition better than those with a diagnosis of more 
than two years and this was unexpected. Perhaps though this might be explained by the very recent 
information received about POAG during diagnosis. In addition, patients’ causal beliefs were also 
interesting; the majority of participants could identify a “true” risk factor for POAG and OHT [24] but 
many also held untrue causal beliefs. Many patients correctly understood POAG/OHT to be largely 
idiopathic and this warrants further study because work in other chronic conditions has shown this 
perception can influence prognosis [27].  
Beliefs about control over POAG/OHT varied widely with, for example, many patients returning low 
scores on questions about how much treatment can help. This may have arisen because of confusion 
over illness cures rather than illness control. Yet, a negative outlook about treatment potential has 
been shown to impact on well-being and adherence to treatment in other chronic disease [28, 29, 
30]. Patients who do not think their medication is useful may not take it, especially if they also feel 
that their condition is not long-term [31].This finding reinforces the importance of communicating 
the important message about necessity of adhering to a life-long treatment to people with 
POAG/OHT. 
A notable finding is the similarity in illness perceptions between patients with ocular hypertension 
(OHT) and manifest glaucoma (POAG). Long-term prognosis for OHT patients is relatively good, with 
only a small number developing POAG [32]. Our findings indicate OHT patients may need different 
information at diagnosis to help improve perceptions surrounding the consequences of their illness 
and to make sure they understand their diagnosis is different to a diagnosis of manifest glaucoma.  
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Our study had several strengths. For example, the cases and those with a diagnosis of more than two 
years were stratified and related by age and disease severity. Patients with any other significant 
ocular co-morbidity were excluded to help ensure that BIPQ scores were reflective of the patients’ 
experience of their POAG/OHT. Moreover, our analysis took account of self-reported general health 
(albeit with a relatively blunt tool [EQ5D]) and distressed personality as confounders of response to 
BIPQ. Furthermore, sample sizes were large enough to support our finding of no differences in 
average BIPQ across our groups. Newly-diagnosed patients were recruited by the same clinician at 
diagnosis, ensuring continuity of information but this did not allow for testing of variation in 
response if, for example, diagnosis had been given by different doctors. 
There are several limitations to our study. People were only recruited from two clinical centres in 
England, were nearly all Caucasian and a significant proportion were well educated, to a graduate or 
professional level. Previous studies have found racial differences in illness perceptions [33] but there 
is evidence that general education level may not be associated with illness perceptions [34]. Our 
results may have been subject to volunteer bias too; we did not collect data on people who chose 
not to participate or who did not return questionnaires packs. Moreover, we did not record 
information about patients’ co-morbidities and many elderly people have more than one chronic 
illness [35]. Still we mediated this limitation by using a measure of self-reported general health 
(EQ5D) [36] and corrected our analyses for this. 
Findings from this study suggest avenues for future research. Investigations into treatment beliefs 
may lead to important information to improve adherence rates to medications as suggested by 
another study in people with glaucoma [37]. A study exploring, in more detail, self-reported outlook 
and prognosis for people with OHT and how this ought to differ from patients diagnosed with 
glaucoma with VF loss would be interesting. A follow-up study to look at the impact of more detailed 
post diagnosis education would be worth considering, especially as the BIPQ scores for “how much 
control do you think you have over your OHT/OAG” and “how much do you think your treatment can 
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help you OHT/OAG” were disappointingly low.  A study examining a wide demographic of patients 
from different clinical centres would be useful. Moreover, a cohort study could follow the same 
patients to investigate changing illness perceptions in the same individuals over time.  
To conclude, overall illness perceptions in newly-diagnosed patients are similar to those with more 
experience of the condition in glaucoma and ocular hypertension. There were some differences on 
individual domains of the BIPQ, notably the experience of symptoms and beliefs about how long the 
illness would last; for example, many newly-diagnosed POAG patients do not realise their condition 
permanent. Remarkably, people with a diagnosis of OHT had similar negative illness perceptions as 
those people with manifest glaucoma; this is an important finding given the long-term risk of visual 
impairment associated with glaucoma is different to those with OHT. The negative perceptions held 
by OHT patients may highlight the need for better communication about the nature of their 
diagnosis and prognosis.  
  
16 
 
Contributors: DC, TB and CA conceived and designed the study. TB, PT, CA and RB were involved in 
the data collection. LM, PT and DC were involved in the analysis and interpretation of the data. LM 
wrote the first draft of this manuscript. All other authors were involved in the revision and final 
approval of the article.  
Funding: TB was supported by a City, University of London PhD scholarship. LM was supported in 
part by unrestricted funding from Allergan.  
Competing interests: LM: None, TB: None, CA: None, RB: None, PT: None, DC: Allergan, Santen 
(Recipient of Speaker fees) Roche (Financial Support) CenterVue (Consultant).  
Ethics approval: Ethical approval was granted by the North West - Liverpool East NHS Research and 
Ethics committee, England, United Kingdom: 216487.   
17 
 
REFERENCES 
1  Petrie K, Jago LA, Devcich DA. The role of illness perceptions in patients with medical 
conditions. Curr Opin Psychiatry2007;20(2):163-167.  
2  Chen SL, Tsai JC, Chou KR. Illness perceptions and adherence to therapeutic regimens among 
patients with hypertension: a structural modelling approach. Int J Nurs Stud2011;48(2):235-
245.  
3  Rees G, Leong O, Crowston JG  et al. Intentional and unintentional nonadherence to ocular 
hypotensive treatment in patients with glaucoma. Ophthalmology2010;117(5):903-908.  
4  Friedman DS, Hahn SR, Gelb L. Doctor-patient communication, health-related beliefs, and 
adherence in glaucoma: results from the glaucoma adherence and persistency study. 
Ophthalmology2008;115(8):1320-1327.  
5  Saw SM, Gazzard G, Friedman D et al. Awareness of glaucoma, and health-related beliefs of 
patients suffering primary acute angle closure. Br J Ophthalmol2003;87:446-449. 
6  Hartmann CW, Rhee DJ. The patients’ journey: glaucoma. BMJ2006;333:738-739.  
7  Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative 
research study. Eye2009;23(4):924-932.  
8  Jampel HD, Frick KD, Janz NK et al. Depression and mood indicators in newly diagnosed 
glaucoma patients. Am J Ophthalmol2007;144(2):238-244.  
9  Janz NK, Wren PA, Lichter PR et al. Quality of life in newly diagnosed glaucoma patients: The 
Collaborative Initial Glaucoma Treatment Study. Ophthalmology2001;108(5):887-897.  
10  Odberg T, Jakobsen JE, Hultgren SJ et al. The impact of glaucoma on the quality of life of 
patients in Norway. I. Results from a self-administered questionnaire. Acta Ophthalmol 
Scand2001;79(2):116-120.  
11  Glen FC, Crabb DP. Living with glaucoma: a qualitative study of functional implications and 
patients’ coping behaviours. BMC Ophthalmol2015;15:128.  
12  Saunders LJ, Russell RA, Kirwan JF, McNaught AI, Crabb DP. Examining visual fields loss in 
patients in glaucoma clinics during their predicted remaining lifetime. Invest Ophthalmol Vis 
Sci2014;55(1):102-109.  
13  King A, Azuara-Blanco A, Tuulonen A. Glaucoma. BMJ2013;346:f3518 doi: 
10.1136/bmj.f3518.[published Online First: 11 June 2013].   
14  Broadbent E, Wilkes C, Koschwanez H et al. A systematic review and meta-analysis of the Brief 
Illness Perception Questionnaire. Psychology and Health2015;30(11):1361-1385.  
15  Pesut DP, Bursuc BN, Bulajic MV et al. Illness perceptions in tuberculosis by implementation of 
the Brief Illness Perception Questionnaire – A TBNET Study. Springerplus2014;43:664.  
18 
 
16  Frostholm L, Oernboel E, Christensen KS et al. Do illness perceptions predict health outcomes 
in primary care patients? A 2-year follow-up study. J Psychosom Res2007;62(2):129-138.  
17  Scharloo M, Kaptein AA, Weinman J et al. Illness perceptions, coping and functioning in 
patients with rheumatoid arthritis, chronic obstructive pulmonary disease and psoriasis. J 
Psychosom Res1998;44(5):573-585. 
18  French D, Cooper A, Weinman J. Illness perceptions predict attendance at cardiac 
rehabilitation following acute myocardial infarction: A systematic review with meta-analysis. J 
Psychosom Res2006;61(6):757-767. 
19  Broadbent E, Petrie KJ, Main J. The Brief Illness Perception Questionnaire. J Psychosom 
Res2006;60(6):631-637. 
20  Mann DM, Ponieman D, Leventhal H et al. Predictors of adherence to diabetes medications: 
the role of disease and medication beliefs. J Behav Med;32(3):278-284. 
21  EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. 
Health Policy1990;16(6):199-208. 
22  Devlin N, Brooks R. EQ-5D and the EuroQol Group: Past, Present and Future. Appl Health Econ 
Health Policy2017;15(2):127-137. 
23  Denollet J. Type D Personality: A potential risk factor refined. J Psychosom Res2000;49(4):255-
266. 
24  Coleman AL, Miglior S. Risk Factors for Glaucoma Onset and Progression. Surv 
Ophthalmol2008;53(6):3-10. 
25  Petrie KJ & Weinman J. Why illness perceptions matter. Clin Med2006;6(6):536-539. 
26  Hemphill RC, Stephens MAP, Rook KS et al. Older adults’ beliefs about the timeline of type 2 
diabetes and adherence to dietary regimens. Psychol Health2013;28(2):139-153. 
27  Delaney M, Simpson J, Leroi I. Perceptions of cause and control of impulse control behaviours 
in people with Parkinson's disease. Br J Health Psychol2012;17(3):522-535. 
28  Heijmans MJ. Coping and adaptive outcome in chronic fatigue syndrome: Importance of illness 
cognitions. J Psychosom Res1998;45(1):39-51. 
29  Falvo D. Psychosocial and Functional Aspects of Chronic Illness and Disability. In: Falvo, D. 
Medical and Psychosocial Aspects of Chronic Illness and Disability. London, UK: Jones and 
Bartlett Publishers International 2005:1. 
30  Ross S, Walker J, MacLoed MJ. Patient compliance in hypertension: The role of illness 
perceptions and treatment beliefs. J Hum Hypertens2004;18(9):607-613. 
31  Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of 
illness perceptions and treatment beliefs in explaining non-adherence to preventer 
medication. Psychology and Health2002;17(1):17-32. 
19 
 
32  Gordon MO, Beiser JA, Brandt JD et al. The ocular hypertension treatment study: baseline 
factors that predict the onset of primary open-angle glaucoma. Arch 
Ophthalmol2002;120(6):714-720. 
33  Kim Y, Pavlish C, Evangelista LS et al. Racial/ethnic differences in illness perceptions in minority 
patients undergoing maintenance haemodialysis. Nephrol Nurs J2012;39(1):39-49. 
34  Hsiao CY, Chang C, Chen CD. An investigation on illness perception and adherence among 
hypertensive patients. Kaohsiung J Med Sci2012;28(8):442-447. 
35  Barnett K, Mercer SW, Norbury M et al. Epidemiology of multimorbidity and implications for 
health care, research, and medical education: a cross sectional study. 
Lancet2012;380(9836):37-43. 
36  Van Nispen RM, de Boer MR, Hoeijmakers JG et al. Co-morbidity and visual acuity are risk 
factors for health-related quality of life decline: five-month follow-up EQ-5D of visually 
impaired older patients. Health Qual Life Outcomes2009;25:7-18. 
37  Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv 
Ophthalmol2008;53(1):57-68. 
  
 
 
 
